Advaxis signs agreement with Cobra for manufacture of Lovaxin C vaccine
US company Advaxis has signed an agreement with UK-based Cobra Biomanufacturing for the manufacture of its Phase II clinical trial material of a therapeutic cervical cancer vaccine known as Lovaxin C. Cobra has been supporting the clinical programme since 2003.
US company Advaxis has signed an agreement with UK-based Cobra Biomanufacturing for the manufacture of its Phase II clinical trial material of a therapeutic cervical cancer vaccine known as Lovaxin C. Cobra has been supporting the clinical programme since 2003.
Based in North Brunswick, New Jersey, Advaxis is developing therapeutic cancer vaccines that enhance the immune system's cancer-fighting abilities through its proprietary Listeria monocytogenes-based system. Advaxis is the exclusive licensee of a patented broadly enabling Listeria platform technology that can elicit effective anti-tumor responses.
Advaxis' lead Listeria vaccine candidate, Lovaxin C, targets cervical and head and neck cancers. Further Listeria vaccines in development target breast, ovarian and lung cancers. Advaxis has entered a Phase I/II clinical trial. The Listeria platform will also have applications in the fields of infectious disease and autoimmune disorders.
"We look forward to continuing our relationship with Cobra as we move forward with the development of live Listeria vaccines for the treatment of cancer," said John Rothman, Avaxis vice president, clinical development. "Our initial clinical work demonstrated the real world utility of our concepts, and Cobra's ability to execute their production as potential cancer immunotherapeutic agents."